The Science Behind Biologics and Biosimilars

Kelley D. Mayden, MSN, FNP, AOCNP
Wellmont Cancer Institute

The introduction of biologics into oncology has been groundbreaking.  At a time when many of the “innovator drug” patents expire the new frontier is becoming biosimilars.  Unlike established medications, biosimilars and biologics are not chemically synthesized.  This activity explains fundamental differences in the complexity of biosimilars, nomenclature, prescribing, documentation and patient education/consent – indispensable information for the oncology AP.


Download Podcast


Download Transcript


Download Slides


Download Slides & Transcripts


These CE/CME/CEU accredited activities are jointly provided by

JADPRO Logo    Harborside Press Logo    APSHO Logo    Annenberg Logo
Copyright © 2016 Harborside Press, LLC All rights reserved.                Home | Current Issue | Previous Issue | Submissions | About JADPRO | Advertising | Privacy Policy | Contact
Copyright Notice/Disclaimer
Bot trap - Don't go here